How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?

Larotrectinib for treating NTRK fusion-positive solid tumours

Open for comments Open until   Request commenting lead permission

We have updated this service so that members of the same organisation can now collaborate on a joint online response.

Read our blog to learn more.

2 Information about larotrectinib

Marketing authorisation indication

2.1

Larotrectinib (Vitrakvi, Bayer) 'as monotherapy is indicated for the treatment of adult and paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion:

  • who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and

  • who have no satisfactory treatment options'.

Dosage in the marketing authorisation

Price

2.3

The cost of larotrectinib (excluding VAT; BNF online, accessed March 2026) is:

  • £14,000 per 56-pack of 100-mg capsules

  • £3,500 per 56-pack of 25-mg capsules

  • £5,000 per 100‑ml vial of 20‑mg per ml oral solution.

2.4

The company has a commercial arrangement, which would have applied if larotrectinib had been recommended.

Sustainability

2.5

Information on the Carbon Reduction Plan for UK carbon emissions for Bayer will be included here when guidance is published.